Why anti-cancer drugs do not always live up to expectations

For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" ...

New tool offers personalized approach to blood cancer care

Researchers have developed a new tool to help clinicians tailor personalized treatment plans for patients with a rare blood cancer called chronic myelomonocytic leukemia (CMML). The tool, called the international CMML Prognostic ...

page 1 from 31